Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

In a challenging market environment, Adc Therapeutics SA (ADCT) stock has reached a 52-week low, trading at $1.42, with a market capitalization of $138 million. According to InvestingPro analysis, the ...

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

The RSU award will vest in equal annual installments on the first four anniversaries of February 15, 2025, subject to the employee’s continued service with Mersana on each such vesting date. The RSU ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

To stay up to date on Akari’s recent developments on the Webull Corporate Connect Services Platform, current Webull users can follow AKTX from the app on their smartphone or table device. To download ...

In a report released on January 21, Kelly Shi from Jefferies maintained a Buy rating on ADC Therapeutics (ADCT – Research Report), with a price ...